Innate Pharma Net Income

Innate Pharma (IPHA) currently reports a net income of $-86M as of December 2025. That compares with $-25M in the prior-year period — down 249.9% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Innate Pharma's net income history and peer comparisons.

Innate Pharma's net income decreased from $-25M to $-86M — a 249.9% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Innate Pharma's net income of $-86M is lower than the Healthcare sector average of $16B. That is roughly 100.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Innate Pharma reported $-86M in net income as of December 2025. That compares with $-25M in the prior-year period — down 249.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-86M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Innate Pharma, and consider following IPHA for alerts when major investors trade the stock.